Matthijs Moerland studied Biomedical Sciences and Molecular Sciences, and was trained at the department of Cell Biology at Erasmus University Rotterdam. He obtained his PhD investigating lipoprotein metabolism and atherogenesis in humanised animal models. He joined CHDR in 2007 as a Senior Clinical Scientist, and obtained his registration as clinical pharmacologist. Since 2014, Matthijs holds a positions as Research Director. He is leading CHDR’s in-house R&D lab, utilizing cell-based assays for monitoring of drug activity in clinical studies, and in mechanistic ex vivo studies on primary human cells. In addition, Matthijs is heading CHDR’s clinical immuno-cardiovascular research group, with as primary focus the development and application of in vivo immune challenge models (e.g. intravenous and intradermal endotoxin challenges, neoantigen vaccination, topical immune challenges).